Cost-effectiveness analysis of ritonavir boosted nirmatrelvir for adult outpatients with mild to moderate COVID-19 in a European health system
Philip Wikman‐Jorgensen, José María Miralles Ibarra, Carlos Devesa García, Jorge Peris, Jara Llenas‐García
Topics & Concepts
MedicineRitonavirCoronavirus disease 2019 (COVID-19)TocilizumabInternal medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical trialClinical endpointVirologyDiseaseViral loadHuman immunodeficiency virus (HIV)Antiretroviral therapyInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing